• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC TO-I/A filed by REGENXBIO Inc.

    7/1/26 9:10:28 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGNX alert in real time by email
    SC TO-I/A 1 rgnx-to-i-a-1.htm SC TO-I/A SC TO-I/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE TO

     

    (Amendment No. 1)

    (Rule 13a-4)

    Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)

    of the Securities Exchange Act of 1934

     

    REGENXBIO Inc.

    (Name of Subject Company (Issuer) and Filing Person (Offeror))

     

    Options to Purchase Common Stock, Par Value $0.0001 per share

    (Title of Class of Securities)

     

    75901B107

    (CUSIP Number of Class of Securities)

     

    Curran Simpson

    President and Chief Executive Officer

    REGENXBIO Inc.

    9804 Medical Center Drive

    Rockville, Maryland 20850

    (240) 552-8181

    (Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Person)

     

    With Copies to:

     

    Patrick J. Christmas

    Executive Vice President, Chief Strategy and Legal Officer

    REGENXBIO Inc.

    9804 Medical Center Drive

    Rockville, Maryland 20850

    (240) 552-8181

    Kerry Shannon Burke

    Matthew C. Franker

    Covington & Burling LLP

    One CityCenter

    850 Tenth Street N.W.

    Washington, D.C. 20001

    (202) 662-6000

     

     

    ☐

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

     

    Check the appropriate boxes below to designate any transactions to which the statement relates:

     

    ☐

    third party tender offer subject to Rule 14d-1.

    ☒

    Issuer tender offer subject to Rule 13e-4.

    ☐

    going-private transaction subject to Rule 13e-3.

    ☐

    amendment to Schedule 13D under Rule 13d-2.

     

    Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

     

    If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

     

    ☐

    Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

    ☐

    Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

     

     


    This Amendment No. 1 to Schedule TO (together with any exhibits and annexes attached hereto, this “Amendment No. 1”), is filed by REGENXBIO Inc., a Delaware corporation (the “Company”), and amends and supplements the Tender Offer Statement on Schedule TO filed by the Company with the Securities and Exchange Commission on June 3, 2026 (the “Schedule TO”). The Schedule TO relates to an offer by the Company (the “Exchange Offer”) to certain non-executive employees to exchange some or all of their eligible outstanding options to purchase shares of the Company’s common stock for replacement options to purchase shares of the Company’s common stock, upon the terms and subject to the conditions set forth in the Offer to Exchange Eligible Options for Replacement Options dated June 3, 2026 (the “Offer to Exchange”), included as Exhibit (a)(1)(A) to the Schedule TO and incorporated herein by reference.

    This Amendment No. 1 is being made to reflect certain updates as described below. Except as otherwise set forth in this Amendment No. 1, the information set forth in the Schedule TO and the exhibits filed therewith remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment No. 1. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO. You should read this Amendment No. 1 together with the Schedule TO and the Offer to Exchange.

    Item 12. Exhibits.

     

    Exhibit

    Number

    Description

    (a)(1)(A)*

     

    Offer to Exchange Eligible Options for Replacement Options, dated June 3, 2026

     

     

     

    (a)(1)(B)*

     

    Communication to Employees from Chief People Officer, sent on June 3, 2026

     

     

     

    (a)(1)(C)*

     

    Form of Announcement Email

     

     

     

    (a)(1)(D)*

     

    Terms of Election

     

     

     

    (a)(1)(E)*

     

    Form of Confirmation Email

     

     

     

    (a)(1)(F)*

     

    Form of Reminder Email

     

     

     

    (a)(1)(G)*

     

    Screenshots of Option Exchange Website

     

     

     

    (a)(1)(H)*

     

    Option Exchange Frequently Asked Questions

     

     

     

    (a)(1)(I)*

     

    Employee Presentation

     

     

     

    (a)(1)(J)

     

    Communication to Eligible Employees from Chief People Officer, sent on July 1, 2026

     

     

     

    (b)

     

    Not applicable

     

     

     

    (d)(1)*

     

    2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 of the Registration Statement on Form S-1/A (File No. 333-206430) filed with the SEC on September 15, 2015)

     

     

     

    (d)(2)*

     

    Form of Restricted Stock Unit Award Agreement for the 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 of the Annual Report on Form 10-K (File No. 001-37553) filed with the SEC on March 1, 2021)

     

     

     

    (d)(3)*

     

    Form of Stock Option Award Agreement for the 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 of the Annual Report on Form 10-K (File No. 001-37553) filed with the SEC on March 1, 2021)

     

     

     

    (d)(4)*

     

    REGENXBIO Inc. 2025 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 of the Registration Statement on Form S-8 (File No. 333-288040) filed with the SEC on June 13, 2025)

     

     

     

    (d)(5)*

     

    Form of Restricted Stock Unit Award Agreement for the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 of the Quarterly Report on Form 10-Q (File No. 001-37553) filed with the SEC on August 7, 2025)

     

     

     

    (d)(6)*

     

    Form of Stock Option Award Agreement for the 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 of the Quarterly Report on Form 10-Q (File No. 001-37553) filed with the SEC on August 7, 2025)

     

     

     

    (d)(7)*

     

    2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 of the Registration Statement on Form S-1/A (File No. 333-206430) filed with the SEC on September 8, 2015)

     

     

     

    (g)

     

    Not applicable

     

     

     

    (h)

     

    Not applicable

     

     

     

    107*

     

    Filing Fee Table

     

    * Previously filed.

     


    SIGNATURES

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

     

     

    REGENXBIO INC.

     

     

     

     

    Date:

    July 1, 2026

    By:

    /s/ Curran Simpson

     

     

     

    President and Chief Executive Officer

     

     


    Get the next $RGNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RGNX

    DatePrice TargetRatingAnalyst
    1/28/2026$37.00Overweight
    Barclays
    2/11/2025$38.00 → $14.00Buy → Neutral
    Goldman
    2/7/2025$27.00Outperform
    Raymond James
    11/15/2024$22.00Overweight
    Morgan Stanley
    10/10/2024$18.00Outperform
    Raymond James
    6/7/2024$38.00Buy
    Goldman
    3/11/2024$36.00Buy
    H.C. Wainwright
    3/8/2024$20.00 → $35.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $RGNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Simpson Curran was granted 2,404 shares and covered exercise/tax liability with 6,818 shares, decreasing direct ownership by 1% to 338,053 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    7/6/26 4:51:42 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Pakola Steve exercised 2,161 shares at a strike of $7.86 and sold $29,476 worth of shares (2,161 units at $13.64) as part of a pre-agreed trading plan (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    7/6/26 4:51:18 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Pakola Steve exercised 36,725 shares at a strike of $7.86 and sold $688,756 worth of shares (56,333 units at $12.23) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 213,009 units (SEC Form 4)

    4 - REGENXBIO Inc. (0001590877) (Issuer)

    7/1/26 8:08:30 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

    One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroidsPrevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids Topline data from wet AMD pivotal studies, ATMOSPHERE® and ASCENT®, expected in Q4 2026ROCKVILLE, Md.,, July 18, 2026 /PRNewswire/ -- R

    7/18/26 2:55:00 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

    ROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a price of $8.9999 per warrant, in each case before underwriting discounts and commissions. The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, are expected to be approximately $100.0 million. This offering is expected to close on July 20, 2026, subject to customary closing conditions. In addition, REGENXBIO has granted the underwriters a 30

    7/17/26 7:00:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Proposed Public Offering of Common Stock

    ROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, REGENXBIO intends to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of common shares sold in connection with the offering.Morgan Stanley, J.P. Morgan, Leerink Partners and Mizuho are acting as joint book-runni

    7/16/26 4:26:00 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    SEC Filings

    View All

    SEC Form 8-K filed by REGENXBIO Inc.

    8-K - REGENXBIO Inc. (0001590877) (Filer)

    7/20/26 7:34:30 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by REGENXBIO Inc.

    424B5 - REGENXBIO Inc. (0001590877) (Filer)

    7/17/26 5:29:44 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form FWP filed by REGENXBIO Inc.

    FWP - REGENXBIO Inc. (0001590877) (Subject)

    7/16/26 9:54:04 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on REGENXBIO with a new price target

    Barclays resumed coverage of REGENXBIO with a rating of Overweight and set a new price target of $37.00

    1/28/26 7:18:39 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO downgraded by Goldman with a new price target

    Goldman downgraded REGENXBIO from Buy to Neutral and set a new price target of $14.00 from $38.00 previously

    2/11/25 7:12:20 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on REGENXBIO with a new price target

    Raymond James resumed coverage of REGENXBIO with a rating of Outperform and set a new price target of $27.00

    2/7/25 8:29:59 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Leadership Updates

    Live Leadership Updates

    View All

    Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/6/24 6:29:00 PM ET
    $AMTM
    $APO
    $CMA
    Real Estate
    Investment Managers
    Finance
    Major Banks

    REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

    Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programsVit Vasista steps down following more than 15 years at the CompanyROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raising capital, business development transactions and operations for nearly 20 years.  "We are excited to welcome Mitchell at this exciting time for REGENXBIO," said Curran Simpson, President and

    9/17/24 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Announces Leadership Transition

    Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down as President and CEO; Named Chairman of the Board ROCKVILLE, Md., June 12, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that Curran Simpson, Chief Operating Officer, has been appointed as President, Chief Executive Officer and a member of the Board of Directors, effective July 1, 2024. Co-Founder Kenneth T. Mills will step down as President and Chief Executive Officer following 15 years of leadership at the Company, and he is taking on an expanded role on the Board as Chairman. In connection with these changes, Board member Daniel Tassé has been appointed as RE

    6/12/24 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Financials

    Live finance-specific insights

    View All

    REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

    Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE® study of RGX-202Primary endpoint achieved with high statistical significanceStatistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA, n=9), supporting validity of surrogate endpoint Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track toward key catalysts Sites activated in pivotal Phase IIb/III study for diabetic retinopathy; first patient dosed expected Q2 2026Subretinal wet AMD topline pivotal data expected in Q4 2026Clinical hold lifted for RGX-121Webcast today at 8:00 a.m. ET to discuss RGX-202 topline pivotal data and Q1 2026 earnings ROCKVILL

    5/14/26 7:10:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026Robust patient enrollment continues in confirmatory trialSurabgene lomparvovec (sura-vec, ABBV-RGX-314) subretinal wet AMD topline pivotal data expected in Q4 2026; first patient dosed in pivotal Phase IIb/III trial in diabetic retinopathy expected in Q2 2026Company to engage FDA on potential path forward for RGX-121Conference call today at 8:00 a.m. ETROCKVILLE, Md., March 5, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today reported financial results and operational highlights f

    3/5/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    ROCKVILLE, Md., Feb. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced that it will host a conference call on Thursday, March 5, at 8:00 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and operational highlights.Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology comp

    2/25/26 7:05:00 AM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $RGNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/14/24 9:00:57 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/12/24 4:47:45 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

    SC 13G/A - REGENXBIO Inc. (0001590877) (Subject)

    11/4/24 1:49:56 PM ET
    $RGNX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care